SCHEDULE: Forte Biosciences: Boothbay Fund Management Cuts Stake

Boothbay Fund Management and Ari Glass disclose a reduced passive stake of 0.8% in Forte Biosciences, Inc. common stock.

Summary

• Boothbay Fund Management, LLC and Ari Glass have filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Forte Biosciences, Inc.
• As of June 30, 2025, they collectively beneficially own 53,791 shares of Forte Biosciences, Inc. Common Stock.
• This represents 0.8% of the company's outstanding common stock.
• The shares are held by one or more private funds managed by Boothbay Fund Management, LLC, with Ari Glass serving as the Managing Member.
• Both reporting persons hold shared voting power and shared dispositive power over all 53,791 shares, with no sole power reported.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
• A disclaimer notes that beneficial ownership is disclaimed except to the extent of pecuniary interest, particularly where investment and voting discretion are delegated to subadvisors and cannot be terminated within sixty days.

Sentiment

Score: 5

Explanation: Neutral. This is a factual disclosure of a passive ownership stake, not an announcement of company performance or strategic initiatives. The reduction in stake from a previous filing (implied by 'Amendment No. 1' and the low percentage) is a neutral event from a sentiment perspective, as it represents a fund's portfolio adjustment.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Provides transparency on a significant investor's reduced stake, which could be interpreted differently by the market, though the current stake is small.

Key Dates

Keywords

Forte Biosciences, Boothbay Fund Management, Ari Glass, SEC filing, Schedule 13G, beneficial ownership, common stock, investment management, passive investment